Holen Sie sich die Stockscreener-App
31.38
0.06%
-0.02
Schlusskurs vom Vortag:
$31.40
Offen:
$31.39
24-Stunden-Volumen:
3.21M
Relative Volume:
1.50
Marktkapitalisierung:
$3.84B
Einnahmen:
$596.96M
Nettoeinkommen (Verlust:
$221.32M
KGV:
18.04
EPS:
1.7397
Netto-Cashflow:
$208.13M
1W Leistung:
+0.03%
1M Leistung:
+0.48%
6M Leistung:
+32.57%
1J Leistung:
+37.57%
1-Tages-Spanne:
$31.37
$31.40
1-Wochen-Bereich:
$31.34
$31.40
52-Wochen-Spanne:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.38 | 3.84B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Inc (CPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Catalyst Pharmaceuticals Inc - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SMID Core Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Institutional Confidence - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
The Technical Signals Behind (CPRX) That Institutions Follow - Stock Traders Daily
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout - Law360
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Angelini Pharma to buy Catalyst (CPRX) for $31.50 per share; virtual vote July 8 - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
Dakota Review Highlights Broad-Based Strength in May 2026 Private Markets Activity - TipRanks
Homogeneous Catalyst Market Growth Outlook to 2035: Trends, Drivers, and Regional AnalysisNews and Statistics - IndexBox
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones - Stock Traders Daily
CPRX PE Ratio & Valuation, Is CPRX Overvalued - Intellectia AI
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
D.R. Horton Inc. (DHI) Q1 2026 Earnings: Slight EPS Beat Amid Mixed Housing ConditionsEarnings Growth Analysis - thelegaladvocate.com
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Hold Rating, Maintains Target Price $31.5 - Moomoo
Catalyst (CPRX) to be acquired by Angelini Pharma for $31.50 per share (cash) - Stock Titan
H.C. Wainwright Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Technical Reactions to CPRX Trends in Macro Strategies - Stock Traders Daily
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story - Yahoo Finance
Third Avenue Management's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y - MSN
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story - Sahm
Catalyst Pharmaceuticals, Inc.Common Stock (NQ: CPRX - FinancialContent
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm
Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha
CPRX SWOT Analysis: Strong Financials Amidst Market Challenges R - GuruFocus
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Trading the Move, Not the Narrative: (CPRX) Edition - Stock Traders Daily
Catalyst Pharmaceuticals earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals (CPRX) Announces Suspension of Guidance Updates - GuruFocus
Catalyst Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
CPRX Reports Impressive Q1 Revenue Growth - GuruFocus
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance - TipRanks
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals 1Q EPS 50c >CPRX - Moomoo
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):